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Abstract
Background & Aims—The gold standard in assessing liver fibrosis is biopsy despite limitations
like invasiveness and sampling error and complications including morbidity and mortality.
Therefore, there is a major unmet medical need to quantify fibrosis noninvasively to facilitate
early diagnosis of chronic liver disease and provide a means to monitor disease progression. The
goal of this study was to evaluate the ability of several magnetic resonance imaging (MRI)
techniques to stage liver fibrosis.
Methods—A gadolinium (Gd)-based MRI probe targeted to type I collagen (termed EP-3533)
was utilized to noninvasively stage liver fibrosis in a carbon tetrachloride (CCl4) mouse model and
the results were compared to other MRI techniques including relaxation times, diffusion and
magnetization transfer measurements.
Results—The most sensitive MR biomarker was the change in liver:muscle contrast to noise
ratio (ΔCNR) after EP-3533 injection. We observed a strong positive linear correlation between
ΔCNR and liver hydroxyproline (i.e. collagen) levels (r=0.89) as well as ΔCNR and conventional
Ishak fibrosis scoring. In addition, the area under the receiver operating curve (AUR0C) for
distinguishing early (Ishak ≤3) from late (Ishak ≥ 4) fibrosis was 0.942±0.052 (p<0.001). By
comparison, other MRI techniques were not as sensitive to changes in fibrosis in this model.
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Conclusions—We have developed a MRI technique using a collagen-specific probe for
diagnosing and staging liver fibrosis, and validated it in the CCl4 mouse model. This approach
should provide a better means to monitor disease progression in patients.
Keywords
fibrosis; MRI; molecular imaging; type 1 collagen; noninvasive; gadolinium; EP-3533; CCl4
INTRODUCTION
Liver fibrosis is the result of repeated hepatic injury which causes the chronic activation of
tissue repair mechanisms to replace necrotic tissue with extracellular matrix scar [1].
Historically, liver fibrosis was a consequence of alcohol excess or hepatitis B or C infection,
but recent increases in non-alcoholic steatohepatitis as a result of diabetes, fatty liver disease
and the metabolic syndrome have increased the prevalence of liver fibrosis. If the underlying
cause of disease is suppressed or removed early enough, liver fibrosis has the potential to
regress to a lesser stage or even reverse to a normal architecture [2]. However, if left
unchecked, fibrosis will progress to cirrhosis, an advanced stage of the disease estimated to
affect 1–2% of the world’s population [3–4]. The major clinical consequences of cirrhosis
are impaired liver function and development of hepatocellular carcinoma (HCC), both of
which increase the risk of death. Therefore, there exists a major unmet medical need for
techniques that can be used to identify disease progression in patients as well as to monitor
response to therapy.
The gold standard in assessing liver fibrosis is biopsy despite several limitations [5]. For
example, significant complications following liver biopsy, defined as requiring hospital
admission or prolonged hospital stay, occur in 1–5% of patients and mortality has been
reported between 0.01 and 0.1% [6–7]. In addition, biopsy suffers from sampling error,
inter-observer variability and does not sample differences in disease across the entire organ.
Of note, even for advanced stages of liver fibrosis such as cirrhosis, error rates in diagnosis
of 33% have been reported [8]. Repeated biopsies to evaluate disease progression or
response to treatment are unattractive due to patient compliance and increased risk of
complications. For all of these reasons, noninvasive strategies that can repeatedly assess
liver fibrosis throughout the whole organ are urgently needed.
Unfortunately, conventional imaging has not been able to detect liver fibrosis at a mild to
moderate stage although elastography has shown promise in recent years [9]. Since liver
fibrosis is characterized by excess deposition of extracellular matrix proteins including type
I collagen, we hypothesized that a magnetic resonance imaging (MRI) agent providing a
measure of collagen levels would have broad utility in not only staging liver fibrosis but also
monitoring response to treatment. Type I collagen is an attractive target because its
concentration increases as fibrosis progresses [10] and its extracellular location makes it
readily accessible to the probe. MRI offers several technical advantages compared to other
imaging techniques including its deep tissue penetration, high spatial resolution and
complete coverage of the entire liver. In addition, MRI does not require ionizing radiation
which is beneficial in monitoring a disease that is known to take years to progress or regress
and thus would most likely require several rounds of imaging.
Previously, we identified a 16 amino acid peptide that had specificity for type 1 collagen and
functionalized it for MRI through the addition of 3 GdDTPA chelators. We demonstrated
that this compound, termed EP-3533, bound reversibly (Kd=1.8 μM) and non-saturably to
type I collagen and could be used to detect myocardial scar [11]. Recently, we demonstrated
that EP-3533 could identify the presence of advanced liver fibrosis in two rodent models
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(diethylnitrosamine-treated rats and carbon tetrachloride (CCl4)-treated mice) [12].
However, that pilot feasibility study was not powered to stage fibrosis as the animals were
only imaged at a single time point. Here, we show that EP-3533 can reliably distinguish
different stages of disease in the CCl4 mouse model. We also compared EP-3533 enhanced
MRI to other MRI techniques previously reported to detect fibrosis, such as diffusion and
relaxation time measurements. In addition, we performed biodistribution, pharmacokinetics,
and in vitro pharmacology studies to evaluate the safety of EP-3533.
MATERIALS AND METHODS
Animal models
All experiments were performed in accordance with the NIH Guide for the Care and Use of
Laboratory Animals and were approved by the institution’s animal care and use committee.
Strain A/J male mice (Jackson Laboratories, Bar Harbor, ME) were administered 0.1 mL of
a 40% solution of CCl4 (Sigma, St. Louis, MO) in olive oil by oral gavage three times a
week for either 6, 12 or 18 weeks to induce fibrosis at different stages (n=6 for all time
points). Controls received only pure olive oil. Animals were imaged one week after the last
injection to avoid acute effects of CCl4.
Probe
EP-3533 comprises a ten amino acid cyclic peptide conjugated to three gadolinium (Gd)
moieties, and was synthesized as previously reported [11]. The peptide confers affinity for
type I collagen and the Gd moieties provide strong signal enhancement (relaxivity=16.2
mM−1s−1 (5.4 per Gd ion) at 4.7T) [13].
MR imaging and analysis
Animals were anesthetized with isoflurane (1–2%) and placed in a specially designed cradle
with body temperature maintained at 37°C. The tail vein was cannulated for intravenous (iv)
delivery of the contrast agent while the animal was positioned in the scanner. Imaging was
performed at 4.7T using a small bore animal scanner (Bruker Biospec) with a custom-built
volume coil. In our pilot feasibility study, we used a somewhat arbitrary dose of 20 μmol/kg
EP-3533 for MR imaging of liver fibrosis [12]. A high dose of EP-3533 will result in greater
MR signal enhancement but could also saturate the target (i.e. collagen) and lead to non-
specific enhancement. Therefore, we reasoned that it would be possible to increase the
sensitivity of our prior technique through dose optimization of the probe. We evaluated
doses of 5, 10, 20, and 40 μmol/kg and chose a dose of 10 μmol/kg for subsequent studies.
The imaging paradigm involved a series of baseline images, followed by a bolus iv injection
of EP-3533, and further imaging out to 45 minutes post injection. The baseline imaging
included T1, T2, T1, apparent diffusion coefficient (ADC), and magnetization transfer ratio
(MTR) quantification. Imaging protocols were similar to those used in other rodent MRI
studies [12, 14–17]. In order to minimize the overall imaging time, we only performed 2–3
of these baseline scans per mouse and these baseline scans were randomized over the
population. Details of the MRI acquisition parameters are given in the Supporting
Information.
MTR is calculated as: MTR=[(S0−S)/S0], where S0 is the signal obtained without pre-
saturation, and S is the signal obtained with pre-saturation. ADC is calculated from fitting
the change in signal intensity as a function of b-value: S/S0=exp(−b*ADC). T1 is calculated
from a 3 parameter fit (T1, S0, A) of the dependence of signal intensity (S) on inversion time
(TI): S=S0[1− A*exp(−TI/T1)]. T2 is calculated from the change in signal intensity as a
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function of echo time (TE): S/S0=exp(−TE/T2). T1 is calculated from the change in signal
intensity as a function of spin lock time (SL): S/S0=exp(−SL/T1).
Tissue analysis
Formalin-fixed samples were embedded in paraffin, cut into 5 μm-thick sections and stained
with Sirius red according to standard procedures. Sirius red stained sections were analyzed
by a pathologist, who was blinded to the study, to score the amount of liver disease
according to the method of Ishak. Hydroxyproline in tissue was quantified by HPLC
analysis as previously described [18]. Gd was quantified in tissue acid digests by inductively
coupled plasma-mass spectrometry using dysprosium as an internal standard.
Hydroxyproline and Gd are expressed as amounts per wet weight of tissue.
Statistics
All data are shown as mean±SEM. Differences among groups were tested with repeated
measures ANOVA followed by Student-Newman-Keuls post hoc test. A Kruskal-Wallis test
followed by post hoc Dunn-Holland-Wolfe test was performed to assess differences in Ishak
scores. The Pearson correlation coefficient was computed to assess quality of linear
correlations and a t-statistic was calculated based on the null hypothesis that the correlation
coefficient was zero. Receiver operating curve (ROC) analysis was performed using Prism 6
(GraphPad software). p<0.05 was considered as significant.
RESULTS
Dose optimization of EP-3533 was done in mice treated with CCl4 for 18 weeks which
causes advanced fibrosis as illustrated by Sirius red staining (Supp. Fig. 1). MRI was
performed with four doses of EP-3533 (5, 10, 20 or 40 μmol/kg) in the fibrotic CCl4-treated
mice and controls that had no fibrosis. In order to find the optimal dose for distinguishing
fibrosis, we quantified the percentage of signal enhancement in the liver at 40 min post
EP-3533 injection compared to the liver signal prior to probe injection. As expected, liver
signal enhancement increased as the dose increased, but the ability to distinguish fibrotic
animals from controls diminished with increasing dose (Supp. Fig. 1). By comparison, at the
lowest dose there was good discrimination between fibrotic and control animals, but the
signal enhancement was low resulting in a larger relative error. A dose of 10 μmol/kg could
reproducibly discriminate fibrotic animals from controls and was therefore chosen for all the
remaining studies.
Before EP-3533 can be successfully translated into a clinical setting, it is necessary to have
an understanding of its pharmacokinetics. To address this issue, we performed 3D T1-
weighted MR imaging of the thorax and abdomen of mice injected intravenously with
EP-3533 in order to estimate signal washout rates from blood and other organs (Supp. Fig.
2). The blood half-life of EP-3533 was 19±2 minutes, consistent with its extracellular
distribution and primary renal clearance as indicated from the strong MR enhancement in
the kidneys and bladder (Supp. Fig. 2). There was no difference in blood half-life in fibrotic
mice versus controls. We also performed a whole body biodistribution analysis of Gd in
order to track the location of EP-3533 at 2 and 24 h post injection (Supp Fig. 2). By 24 h, the
probe was largely eliminated from the body with the exception of a small retention in the
bone and kidneys.
To evaluate potential off-target effects, we ran an in vitro “lead side-effect panel” from
Cerep to measure the ability of EP-3533 to inhibit receptor binding or enzymatic activity in
33 different in vitro assays (Supp. Table 1). EP-3533 was tested at 10 μM and had no
measurable effect in terms of inhibiting receptor binding or enzymatic activity. Taken
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together, these results suggest that EP-3533 is specific for its target and rapidly eliminated
from the body.
In order to determine whether EP-3533 could distinguish early stages of liver fibrosis from
more advanced disease, we treated mice with CCl4 or vehicle control for 6, 12 or 18 weeks
to cause varying stages of liver fibrosis. Mice were MR imaged prior to and immediately
following an iv injection of 10 μmol/kg EP-3533. The baseline MRI also included
measurements of T1 [14], T1ρ [16], T2 [14], ADC [15, 19] and MTR [17] as these
measurements have also been reported to correlate with fibrosis. All the imaging results
were correlated with histological Ishak scoring of liver fibrosis.
As expected, disease progressed in a stepwise fashion in the CCl4 mouse model as
determined by Sirius red staining (Fig. 1A). After 6 weeks of CCl4 administration, most
animals had extensive portal fibrosis with occasional bridging fibrosis (Ishak 2–3), and the
disease progressed to complete bridging fibrosis with appearance of some regenerative
nodules (Ishak 4–5) by 12 to 18 weeks. Consistently, collagen deposition as determined by
hydroxyproline analysis of liver tissue increased along the same pattern as the Ishak score
(Fig. 1B). We also quantified the amount of collagen deposition by calculating the total
amount of Sirius red staining in representative slides from each animal and this
measurement correlated well with Ishak score (Fig. 1C) and liver hydroxyproline levels
(Fig. 1D).
The most sensitive MR measure that we found to relate MR signal to fibrosis was the
change in contrast to noise ratio (CNR) between liver and adjacent skeletal muscle after
injection of EP-3533. For this analysis, we drew a large region of interest on the liver,
excluding any large blood vessels, and measured the signal intensity (SI). We also measured
SI in the dorsal muscle. Noise was estimated from the standard deviation (SD) of SI in the
air adjacent to the animal. CNR was calculated as {(SIliver−SImuscle)/SDair}. We used an
inversion recovery sequence with an inversion time that nulled the signal in the liver prior to
probe injection. This provided the largest dynamic range in liver signal change, as seen in
Fig. 2A where representative images show the anatomy of the mouse in axial view with
stomach, liver and dorsal muscle labeled. The greyscale image shows the anatomical image
at the level where the MR measurement was performed while the false color overlay is the
difference image between the inversion recovery image taken 40 minutes post-injection and
the image taken prior to injection of EP-3533. Post-probe, we see significant enhancement in
the liver of both the control and fibrotic animals, but little enhancement in the muscle. As
expected, we observed much greater enhancement in the liver of the fibrotic animal.
As shown in Fig. 2B, the change in liver:muscle contrast after EP-3533 injection (CNR
liver:muscle) increases with disease progression (Ishak score) in the fibrotic CCl4-injured
mice. Consistently, ex vivo liver Gd levels, another marker for probe uptake, also increased
along with the Ishak score (Fig. 2C). There were also strong correlations between (CNR
liver:muscle) and liver hydroxyproline levels (r=0.89, Fig. 2D) and (CNR liver:muscle) and
Sirius red quantification (r=0.83, Fig. 2E). Both of these latter results highlight the strong
specificity of EP-3533 for collagen. Finally, we calculated the area under the ROC
(AUROC) for detecting fibrosis (Ishak 0 versus Ishak ≥2) to be 0.933±0.059 (95% CI=0.82–
1.05, p=0.0011; Supp. Fig. 3). For distinguishing early from later stages of fibrosis (Ishak ≤3
versus Ishak ≥4), AUROC was calculated as 0.942±0.052 (95% CI=0.84–1.05, p=0.00087;
Supp. Fig. 3).
We also examined other MRI measures that were unrelated to the collagen probe to
determine if MRI alone could be sensitive to liver fibrosis. There have been literature reports
that relaxation time (T1, T2 or T1ρ), diffusion (ADC) and magnetization transfer
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measurements could serve as sensitive markers of liver fibrosis [14–17, 19]. However in this
animal model, we observed only weak correlations of these parameters with liver
hydroxyproline levels (Fig. 3A), and in general, the changes observed were on the order of
the uncertainty in the measurement. Only T1ρ measurements could significantly distinguish
fibrotic animals from controls in terms of Ishak scoring (Fig. 3B), but T1ρ could not
distinguish moderate (Ishak 2–3) from severe (Ishak 4–5) fibrosis. The other MR
measurements (T1, T2, ADC, MTR) could not classify animals into groups based on Ishak
scoring.
The lack of a noninvasive means for assessing liver fibrosis is a major obstacle to the
development of anti-fibrotic drugs [9]. Since there are currently no approved drugs for the
treatment of liver fibrosis, we used the common approach of toxin withdrawal as a model of
fibrosis regression. Mice were treated with CCl4 for 9 weeks to induce liver fibrosis and
then one group of mice continued to receive CCl4 while another group had CCl4 withdrawn.
As can be seen in Fig. 4A–B, withdrawal of CCl4 improved liver disease as assessed by
Sirius red staining. And in fact, histological scoring of the Sirius red staining demonstrated
that on average the Ishak score improved by 2 stages in the mice that had CCl4 withdrawn
(Fig. 4C). MR imaging with EP-3533 could not detect a difference in fibrosis stage between
these two groups of mice (Fig. 4D). Interestingly, a recent report demonstrated that even
though histological improvement of disease was observed after CCl4 withdrawal, total
collagen as assessed by hydroxyproline analysis did not decrease for at least 12 weeks [20].
Consistently, when we analyzed total collagen levels (hydroxyproline) in our animals, we
did not detect a significant difference between the animals that continued to receive CCl4
and those that had it withdrawn (Fig. 4E). These results therefore further highlight the
specificity of EP-3533 to collagen as opposed to liver disease.
DISCUSSION
Here we show for the first time that collagen-enhanced MRI can accurately monitor and
stage liver fibrosis progression in CCl4-treated mice. Further, we observed a remarkable
correlation between MR imaging and total collagen levels as well as a strong correlation
between MR imaging and Ishak score. This result is probably explained by the fact that the
probe is specifically targeting collagen. However, it is also worth noting that while Ishak
scoring suffers from the limitation of biopsy and only represents histological analysis of a
very small sample of the liver, the hydroxyproline analysis was performed on ~20% of the
total liver and therefore might better reflect the extent of fibrosis that is actually present in
the entire liver. This idea is supported by the variation in collagen levels observed within the
same Ishak score and suggests that collagen-enhanced MRI of the entire liver might better
represent disease stage than histological scoring of biopsied liver tissue.
To our knowledge, this is the first report to directly compare several MR measures in the
same fibrotic animals. Relaxation times, ADC and MTR will depend on a number of factors
such as protein content, iron concentration, edema, and extracellular volume. This makes
changes in such parameters difficult to interpret. For instance, increased extracellular
volume may be expected to increase water diffusion, but increased matrix production may
have the opposite effect. In line with what has been observed previously, we observed trends
in how these parameters changed with increasing fibrosis. However, the magnitude of the
change with disease was on the order of the uncertainty in the measurement itself, and this
resulted in relatively weak correlations. The results with these intrinsic MR markers serve to
underscore the significance of our finding with the collagen-targeted probe. Direct
molecular MR imaging of collagen with a targeted probe is much more sensitive to changes
in fibrosis.
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MR elastography (MRE) has shown great promise in staging fibrosis. MRE uses a vibration
source to generate low frequency mechanical waves in tissue, and these waves can be
detected by MRI and processed to give maps of mechanical properties such as liver stiffness.
Because of the additional hardware required for MRE, we were unable to directly compare
our molecular imaging approach with MRE in this study. However the AUROC analysis
performed here to distinguish different stages of fibrosis showed a similar diagnostic
accuracy to MRE [21]. We note that molecular imaging with the EP-3533 is compatible with
MRE, and that the two techniques could be combined for potentially greater accuracy.
There are also several other approaches for the noninvasive assessment of fibrosis [22].
Panels of serum biomarkers, like FibroTest [23] and the enhanced liver fibrosis (ELF) panel
of ECM markers [24], have been developed as predictors of liver fibrosis. In general, most
of these tests can rule-in or rule-out fibrosis, but can not reliably differentiate stages of
fibrosis [9]. Transient ultrasound elastography (FibroScan) has been widely studied [25]. A
recent meta-analysis of 50 transient elastography studies of the liver concluded that the
technique can be performed with excellent diagnostic accuracy and is independent of the
underlying liver disease for the diagnosis of cirrhosis [26]. However, for the diagnosis of
earlier stages of fibrosis, high variability of the ROC was found that is dependent on the
underlying liver disease. Thus, all of these techniques require further evaluation and
optimization, but we believe that collagen-enhanced MRI could be performed along side
these other tests in order to more accurately diagnose liver fibrosis.
It remains to be seen whether collagen-enhanced MR imaging can be used to monitor
fibrosis regression in response to treatment or intervention (for example removal of the
insulting agent, like alcohol, HCV or fatty liver). We tried to use CCl4 withdrawal as a
model of fibrosis regression but observed no changes in total collagen as assessed by
hydroxyproline analysis even though the animals appeared histologically better by Sirius red
staining. This confounding result may be explained by differences in the ability of these
assays to detect collagen once CCl4 has been withdrawn. Our results suggest that collagen is
modified in some way, perhaps just through digestion, which makes it detectable by
hydroxyproline analysis and collagen-targeted MRI but not Sirius red staining. In fact,
recent results from the Schuppan group have also demonstrated a discrepancy between
hydroxyproline analysis and Sirius red staining in monitoring collagen levels after CCl4
withdrawal and they noted that total collagen (as assessed by hydroxyproline) did not
decrease for at least 12 weeks after withdrawal [20]. It is currently unknown for how long
intervention is required to decrease collagen levels in humans. If collagen levels do not
subside for an extended period of time, then EP-3533 might not be as effective in
monitoring disease regression under these situations. However, a variety of fibrolytic agents
that would presumably reduce collagen levels are now under development and it is feasible
that their efficacy could be monitored with EP-3533.
We performed our studies using a high field, dedicated small animal scanner. However, we
anticipate no particular challenges in translating to a clinical setting in a typical 1.5T
scanner. The Gd dose used here (0.03 mmol/kg total) is lower than that of conventional Gd
contrast (0.1 mmol/kg). We also note that the relaxivity of EP-3533 is 3 times higher at 1.5T
than at 4.7T, and thus it may be possible to reduce this dose even further at low field [11,
13]. The most sensitive MR change to fibrosis in this study was simply the change in liver to
muscle CNR when comparing a delayed post-probe image to the baseline image. We used
an inversion prepared turbo spin echo type sequence that is analogous to sequences standard
in body imaging on clinical scanners. Thus in a clinical setting, it should be feasible to
obtain whole liver images in a single breath-hold that would enable a spatially resolved,
whole organ measure of fibrosis.
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It should also be mentioned that the ongoing cycles of injury and repair that lead to
accumulation of scar tissue is similar whether it occurs in response to chronic injury of the
liver or other organs like the kidney or lungs. Cardiac [27], renal [28] and pulmonary
fibrosis [29] are all characterized by excess deposition of type I collagen. Therefore, our
MRI approach to monitor changes in collagen during liver fibrosis should also be applicable
to these other fibrotic pathologies. However, the distribution of the probe to the kidneys will
result in a high background that may make renal fibrosis quantification challenging. The
evaluation of fibrosis in other organ systems is currently under investigation in our
laboratory.
In conclusion, we have shown that EP-3533 is sensitive to changes in type I collagen levels
observed as fibrosis progresses in CCl4-treated mice and that collagen-enhanced MRI can
accurately stage fibrosis in these animals. Since EP-3533 is rapidly excreted and
demonstrates minimal non-specific binding, it should be examined for its ability to detect
liver fibrosis in humans. Combined with other noninvasive strategies like serum tests and
elastography, collagen-enhanced MRI might offer a means to not only better identify which
patients have rapidly progressing disease but also to monitor interventions in these patients.
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Fig. 1. Characterization of a CCl4-induced mouse model of liver fibrosis
(A) Representative images of Sirius red staining after CCl4 administration for 6, 12 or 18
weeks. (B) Total collagen as assessed by hydroxyproline analysis was calculated as disease
progressed as determined by Ishak scoring. (C) Sirius red staining was quantified using
Image J software and compared to disease progression. (D) Correlation between total
collagen (hydroxyproline) and Sirius red quantification. **p<0.001 and ***p<0.0001.
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Fig. 2. Staging of liver fibrosis using collagen-enhanced MRI
(A) Representative axial MR images of a control (Ishak 0) and fibrotic (Ishak 5) mouse
showing the liver, stomach and dorsal muscle. False color overlay is the difference image
between post- and pre-injection images of EP-3533. Both images rendered at the same scale.
(B) ΔCNR(liver:muscle) was calculated as disease progressed as determined by Ishak
scoring. (C) The amount of probe present in the ex vivo liver (% Injected Dose Gd/g Liver)
was calculated as disease progressed as determined by Ishak scoring. (D) Correlation
between ΔCNR(liver:muscle) and total collagen (hydroxyproline). (E) Correlation between
ΔCNR(liver:muscle) and Sirius red quantification. #p<0.05, *p<0.01 and ***p<0.0001.
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Fig. 3. Analysis of other MR measurements for diagnosing liver fibrosis
Correlation of MR measurements with Ishak score and total liver collagen (hydroxyproline,
Hyp). (A) T1 relaxation time vs Ishak; (B) apparent diffusion coefficient (ADC) vs Ishak;
(C) T1ρ relaxation time vs Ishak; (D) T2 relaxation time vs Ishak; (E) magnetization
transfer ratio (MTR) vs Ishak; (F) T1 vs Hyp; (G) ADC vs Hyp; (H) T1ρ vs Hyp; (I) T2 vs
Hyp; (J) MTR vs Hyp. #p<0.05.
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Fig. 4. Collagen-targeted MRI of liver fibrosis after CCl4 withdrawal
(A) Representative images of Sirius red staining of livers from mice treated with either CCl4
for 18 weeks (CCl4) or CCl4 for 9 weeks followed by 9 weeks of withdrawal (Withdrawal).
Control animals received oral gavage of vehicle only. Sirius red staining was (B) quantified
using Image J software or (C) assessed by Ishak scoring. (D) ΔCNR(liver:muscle) was
calculated. (E) Total collagen was determined by hydroxyproline analysis. #p< 0.05,
*p<0.01, **p<0.001 and ***p<0.0001.
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